Clinical Trial Update: A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating the SGT-501 gene therapy for catecholaminergic polymorphic ventricular tachycardia is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Catecholaminergic Polymorphic Ventricular Tachycardia

Drugs mentioned

• SGT-501 (SGT-501)

Snippet

Sponsor: Solid Biosciences Inc. | Conditions: Catecholaminergic Polymorphic Ventricular Tachycardia | Phase 1 | Status: RECRUITING